Hepatocellular Cancer

The most active compounds were further tested in wound-healing assays, where 3lPd almost completely inhibited A549 cell migration at 24 and 48 h, whereas the reference drug cisplatin induced only partial inhibition...In silico studies were performed to investigate their interactions with p53, GAPDH, and c-MYC proteins. Overall, these results suggest that piperidine-bearing hydrazones and their Pt(II)/Pd(II) complexes represent promising scaffolds for the development of novel anticancer agents.

P2, N=36, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Aug 2026

ABT-737 exerts potent antitumor effects through the induction of PANoptosis in hepatocellular carcinoma, providing a promising therapeutic strategy for HCC treatment.

The senescence-ferroptosis-related genes TP53, HIF1A, and CDKN2A demonstrated potential as diagnostic and prognostic biomarkers in HCC. The developed nomogram may support individualized prognostic assessment and inform early diagnostic and therapeutic strategies in patients with HCC.

In conclusion, the dual-targeted OMV system enhances tumor specificity via cooperative GPC3/CD133 recognition, optimizes pH-responsive release, and reduces nonspecific clearance by modulating macrophages. These features improve antitumor efficacy and mitigate toxicity, positioning OMV-based nanocarriers as promising platforms for precision HCC therapy.

Thus, conservative management with close surveillance may be feasible for carefully selected patients with small, asymptomatic tumors. However, additional cases are needed to clarify optimal management strategies.

Early increases in ADC after SBRT of the liver were associated with tumor shrinkage and changes in PIVKA-II, supporting the use of quantitative MRI as an early response biomarker. Larger cohorts with longer follow-up periods are warranted.

This study evaluated a novel combination of DNV3 (anti-LAG-3), toripalimab (anti-PD-1), and chemotherapy (nab-paclitaxel/cisplatin) in 27 Asian patients with unresectable or metastatic melanoma (77.8% [21/27] previously treated with anti-PD-[L]1 and 22.2% [6/27] treatment-naïve mucosal melanoma; subtypes: 13 mucosal, 6 acral, 5 cutaneous, and 3 of unknown primary origin). Therefore, the combination of LAG-3/PD-1 blockade and chemotherapy demonstrated promising efficacy, notably in treatment-naïve mucosal melanoma with liver metastases. (Chinese Clinical Trial Registry number, ChiCTR2400079543).

Furthermore, through computer-simulated clinical trials, we find that reducing the dose of apatinib in combination therapy to 125 mg can still achieve therapeutic effects comparable to the original dose. These findings provide valuable insights for future drug development and clinical trial design.

RAR independently predicts postoperative recurrence or progression in HBV-HCC. The RAR-based nomogram offers a practical tool for individualised estimation of PFS, facilitating more precise postoperative risk stratification and management.

P1/2, N=55, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026

P=N/A, N=200, Not yet recruiting, Sohag University